-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$39.5054.24% Upside
Enliven Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. has been rated by research analysts at Robert W. Baird, Mizuho Securities in the past 90 days.